Shumei Kato
Internal Medicine · Houston, TXNPI 1609025865
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $116,478 of the $180,017 with a category attached, or 64.7%. 8 manufacturers reported payments, led by Foundation Medicine, Inc. at 59.4% of the total. Reporting peaked in 2019 at $47,798 and has fallen 93.4% since, to $3,163 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $2307.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$107K
- F. Hoffmann-la Roche AG$45K
- Chugai Pharmaceutical Co., Ltd.$18K
- Partner Therapeutics, Inc.$3K
- Array Biopharma Inc$3K
- Astrazeneca UK Limited$2K
- plus $1K from 2 others
Across 81 payments — averaging $20,818 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$877K
- Boehringer Ingelheim International GmbH$257K
- Amgen$172K
- Genentech, Inc.$130K
- AbbVie$125K
- Bayer$38K
- plus $88K from 5 others
What the payments were for
- Consulting fees$116,47865%
- Speaking & faculty fees$31,53518%
- Travel & lodging$26,72015%
- Food & beverage$5,2733%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 49 | $106,929 |
| F. Hoffmann-la Roche AG | 11 | $45,473 |
| Chugai Pharmaceutical Co., Ltd. | 8 | $17,909 |
| Partner Therapeutics, Inc. | 6 | $3,352 |
| Array Biopharma Inc | 1 | $3,000 |
| Astrazeneca UK Limited | 1 | $1,943 |
| Bayer | 1 | $1,400 |
| Sysmex America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$106,929
- Non-Covered Product$45,473
- FOUNDATIONFOCUS$12,097
- FOUNDATIONONE HEME$12,097
- FOUNDATIONONE$12,097
- FOUNDATIONONE LIQUID$6,355
- FOUNDATIONACT$5,742
- Bizengri$3,163
- BRAFTOVI$3,000
- Vitrakvi$1,400
How this compares
$180,017 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BalversaErdafitinib | 12 | $167,191 |
| Prochlorperazine Maleate | 19 | $190 |
| Ondansetron Hcl | 17 | $190 |
| Potassium Chloride | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Sukhdeep BasraHouston$168K
- Paolo StratiHouston$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.